8 results
The study objectives are to determine the incidence rate of FVIII inhibitors, frequency of adverse events (AEs), and serious adverse events (SAEs) associated with the use of CSL627, to evaluate the PK of 50 IU/kg CSL627, and to evaluate the efficacy…
To evaluate the efficacy of rVIII-SingleChain in the treatment of major andminor bleeding events based on the investigator*s 4-point assessment scale
This study aims to validate the Corsano CardioWatch 287-2 for the continuous monitoring of heart rate at <= 4 bpm root mean squared error (RMSE); interbeat intervals at <= 50 ms RMSE; breathing rate at <= 2 brpm RMSE; and…
This study aims to evaluate the Corsano Cardiowatch 287-2 for heart rate, heart rate variability (RR intervals), oxygen saturation, respiratory rate, and blood pressure during strenuous activities such as High-Intensity Interval Training (HIIT).…
Primary objective: To compare the number of episodes of atrial fibrillation detected by the Corsano CardioWatch 287-2 during 28 days of use with the number of episodes of atrial fibrillation detected by conventional Holter monitoring during 48 hours…
The objective of the proposed study is to confirm the findings of the dose ranging trial by, primarily, assessing the effect of two doses of CHF6001 on the rate reduction of moderate and severe exacerbations, when added onto maintenance triple…
The objective of the proposed study is to confirm the findings of the dose finding trial by, primarily, assessing the effect of two doses of CHF6001 on the rate reduction of moderate and severe exacerbations, when added onto maintenance triple…
To assess the ability to track blood pressure decrease measured by the Corsano CardioWatch 287-2 after a period of 28 days of antihypertensive drug treatment initiation, uptitration or change in antihypertensive drugs.